"74% of drug rejections were never about science."

Richard speaks with clinical trial manager Sai Tharuni Kethamreddy about how manufacturing quality problems can delay or stop promising drugs, even when the science and clinical data are strong.They discuss FDA rejections, quality debt, batch consistency, and ways biotech leaders can reduce manufacturing risk before submission. Richard also dedicates the episode to a close friend and mentor who recently passed away.